Leonid Poretsky, MD
Endocrinology, Diabetes & Metabolism · New York, NYNPI 1962491811
Payments from drug & device makers
What this record shows
This record is dominated by education: $75 of the $112 with a category attached, or 66.7%. 4 manufacturers reported payments, led by Boehringer Ingelheim at 37.9% of the total. Reporting peaked in 2021 at $59 and has fallen 64.0% since, to $21 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NY, where the typical reported total is $1,058.
Across 5 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$42
- Novo Nordisk$32
- Amgen$21
- Lilly USA, LLC$16
Across 18 payments — averaging $4009.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$56K
- Sanofi US Services Inc.$16K
What the payments were for
- Food & beverage$3733%
- Education$7567%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $42 |
| Novo Nordisk | 1 | $32 |
| Amgen | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
How this compares
$112 in reported general payments places this provider in the 15th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in New York
- John BilezikianNew York$809K
- Anastasios ManessisNew York$656K
- Jason BakerNew York$427K
- Brian LevyNew York$417K
- Stuart WeissNew York$275K
- Priya JaisinghaniNew York$239K
- Henry GinsbergNew York$161K
- Recaredo BerbanoNew York$146K
- Beverly TchangNew York$120K
- Shira EytanNew York$96K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.